Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

PEP02

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A multicenter, open‐label, noncomparative, randomized phase II study (PEPCOL) was conducted to evaluate the efficacy and safety… 
Review
2016
Review
2016
Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents… 
  • figure 1
  • table 1
  • table 2
Review
2016
Review
2016
ABSTRACT Introduction: Systemic chemotherapy remains the standard of care for patients with advanced pancreatic ductal… 
2016
2016
BackgroundPEP02 (also known as MM-398, nal-IRI) is a novel nanoparticle formulation of irinotecan encapsulated in liposomes. The… 
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Highly Cited
2014
Highly Cited
2014
AbstractPurpose To define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02, a… 
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Highly Cited
2013
Highly Cited
2013
Background:PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio… 
  • table 1
  • table 2
  • figure 2
  • table 3
  • figure 3
Highly Cited
2013
Highly Cited
2013
BACKGROUND PEP02 is a novel highly stable liposomal nanocarrier formulation of irinotecan. This randomized phase II study… 
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2011
2011
  • A. Ko, M. Tempero, +6 authors L. Chen
  • Journal of clinical oncology : official journal…
  • 2011
  • Corpus ID: 36258059
237 Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan (CPT-11) that has improved pharmacokinetics and… 
2010
2010
e13024 Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan (CPT-11) that has improved PK and tumor… 
2008
2008
2565 Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan aiming to enhance tumor localization and…